113 results on '"Dasari, Arvind"'
Search Results
2. Quality-adjusted time without symptoms of disease or toxicity (Q-TWiST) analysis of fruquintinib + best supportive care (BSC) compared with placebo + BSC in metastatic colorectal cancer (mCRC): Results from the FRESCO-2 trial.
3. A phase II trial of TAS-102 in patients with colorectal cancer with ctDNA-defined minimal residual disease post-adjuvant therapy compared to synthetic control cohort: Results from the MD Anderson INTERCEPT program.
4. Racial/ethnic representation and disparities in preclinical cancer models.
5. Association of pathologic nodal status with minimal residual disease after neoadjuvant treatment and resection of locally advanced rectal cancer.
6. Clinical characterization and therapeutic outcomes of patients (pts) with colorectal cancer (CRC) harboring somatic BRCA1/2 mutations.
7. A phase II trial of TAS-102 in patients with colorectal cancer with ctDNA-defined minimal residual disease post-adjuvant therapy: Results from the MD Anderson INTERCEPT Program.
8. Redefining the prognostic significance of RAS and BRAF V600E mutations on disease free survival in patients with colorectal cancer in the era of ct-DNA defined minimal residual disease: Results from the MD Anderson INTERCEPT Program.
9. NRG-GI008: Colon adjuvant chemotherapy based on evaluation of residual disease (CIRCULATE-NORTH AMERICA).
10. Prognostic value of circulating tumor DNA (ctDNA) testing in patients (pts) with rectal cancer after neoadjuvant therapy (NAT) and surgery.
11. Natural history and patterns of progression for dMMR/MSI-H colorectal cancer treated with immune checkpoint blockade: A single center retrospective analysis.
12. Impact of KRAS codon-specific mutations on survival of patients with metastatic CRC (mCRC) treated with trifluridine-tipiracil (TAS) plus bevacizumab (Bev): A real-world analysis.
13. INTERCEPT Program of circulating tumor DNA (ctDNA) testing for minimal residual disease (MRD) in colorectal cancer (CRC): Results from a prospective clinical cohort.
14. Systemic Therapy for Tumor Control in Metastatic Well-Differentiated Gastroenteropancreatic Neuroendocrine Tumors: ASCO Guideline
15. Neoadjuvant Pembrolizumab in Localized Microsatellite Instability High/Deficient Mismatch Repair Solid Tumors
16. Health-related quality of life (HRQoL) associated with fruquintinib in the global phase 3, placebo-controlled, double-blind FRESCO-2 study.
17. NRG GI008: Colon adjuvant chemotherapy based on evaluation of residual disease (CIRCULATE-US).
18. Utility of circulating tumor DNA (ctDNA) in the management of appendiceal adenocarcinoma (AA).
19. A randomized phase 2 study of trastuzumab and pertuzumab (TP) compared to cetuximab and irinotecan (CETIRI) in advanced/metastatic colorectal cancer (mCRC) with HER2 amplification: SWOG S1613.
20. ctDNA-based fusion detection for advanced colorectal cancer with a partner-agnostic assay.
21. Phase I/II trial of encorafenib, cetuximab, and nivolumab in patients with microsatellite stable (MSS), BRAFV600E metastatic colorectal cancer.
22. RAS co-mutation and early onset disease represent an aggressive phenotype of atypical (non-V600) BRAF mutant metastatic colorectal cancer.
23. Clinical outcomes following termination of immunotherapy due to long-term benefit in MSI-H colorectal cancer.
24. HER3 expression in metastatic colorectal cancer: Defining the clinicomolecular profile of an emerging target.
25. Prognostic role of systemic inflammatory markers in patients with metastatic MSI-h/dMMR colorectal cancer receiving immunotherapy.
26. Colon adjuvant chemotherapy based on evaluation of residual disease (CIRCULATE-US): NRG-GI008.
27. Phase 2 study of anti-EGFR rechallenge therapy with panitumumab with or without trametinib in advanced colorectal cancer.
28. Efficacy and safety profile of antivascular endothelial growth factor receptor tyrosine kinase inhibitors (avRTKIs) in patients (Pts) with neuroendocrine tumors(NETs): A systematic review and meta-analysis (SRMA).
29. The immune impact of PI3K-AKT pathway inhibition in colorectal cancer.
30. Phase 1/1b trial of fruquintinib in patients with advanced solid tumors: Preliminary results of the dose expansion cohorts in refractory metastatic colorectal cancer.
31. Outcomes of IBD-associated colorectal cancer and implications in early-onset colorectal cancer.
32. Phase I/II trial of encorafenib, cetuximab, and nivolumab in patients with microsatellite stable, BRAFV600E metastatic colorectal cancer.
33. Minimal residual disease assessment in colorectal cancer (MiRDA-C).
34. NRG-GI008: Colon adjuvant chemotherapy based on evaluation of residual disease (CIRCULATE-US).
35. Randomized phase II trial of postoperative adjuvant capecitabine and temozolomide versus observation in high-risk pancreatic neuroendocrine tumors: SWOG S2104.
36. Safety and efficacy of neoadjuvant pembrolizumab in mismatch repair deficient localized/locally advanced solid tumors.
37. Interim analysis results of surufatinib in U.S. patients with neuroendocrine tumors (NETs).
38. Clinical outcomes following definitive treatment of young-onset, locally advanced rectal cancer: A single institution experience.
39. An open-label phase 1b/2 study of surufatinib in combination with tislelizumab in subjects with advanced solid tumors.
40. A novel clinical tool to estimate risk of false negative KRAS mutation in circulating tumor DNA testing.
41. Phase II trial of bintrafusp alfa in patients with metastatic MSI-H cancers following progression on immunotherapy.
42. Utility of circulating tumor DNA in the clinical management of patients with BRAFV600E metastatic colorectal cancer.
43. FRESCO-2: A global phase III study of the efficacy and safety of fruquintinib in patients (pts) with metastatic colorectal cancer (mCRC).
44. Improving the AJCC/TNM staging classification for colorectal cancer: The prognostic impact of tumor deposits.
45. Trends in the incidence and survival outcomes in patients with lung neuroendocrine neoplasms in the United States.
46. Clinical and pathologic factors associated with survival in BRAFV600E colorectal cancers.
47. Efficacy and safety of surufatinib in United States (US) patients (pts) with neuroendocrine tumors (NETs).
48. A randomized study evaluating tailoring of advanced/metastatic colorectal cancer (mCRC) therapy using circulating cell-free tumor DNA (ctDNA) (TACT-D).
49. Impact of antibiotic exposure on the efficacy of immune checkpoint blockade in MSI-H metastatic CRC.
50. A phase II study of durvalumab (MEDI4736) (anti-PD-L1) and trametinib (MEKi) in microsatellite stable (MSS) metastatic colorectal cancer (mCRC).
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.